Scholtz & Company’s NeoGenomics NEO Stock Holding History

Scholtz & Company’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-174,700	Closed	-$1.55M	–	64
2017 Q4	$1.55M	Sell	174,700 -43,875	-20%	-$405K	1.12%	34
2017 Q3	$2.43M	Sell	218,575 -925	-0.4%	-$9K	1.9%	24
2017 Q2	$1.97M	Sell	219,500 -10,025	-4%	-$79.6K	1.7%	28
2017 Q1	$1.81M	Buy	229,525 +10,600	+5%	+$86.3K	1.54%	35
2016 Q4	$1.88M	Buy	218,925 +5,250	+2%	+$45K	1.63%	31
2016 Q3	$1.76M	Buy	213,675 +106,750	+100%	+$896K	1.81%	28
2016 Q2	$860K	Buy	+106,925	New	+$857K	0.88%	31

Other funds holding NEO

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Scholtz & Company's NEO Position: Q1 2018 in Review

Scholtz & Company sold out of NeoGenomics (NEO) in Q1 2018, closing a stake of 174,700 shares — an estimated $1.55M sold.

Scholtz & Company first reported a position in NEO in Q2 2016 and held it in 7 quarters. The position peaked at $2.43M in Q3 2017. 137 funds tracked by Wall St. Rank hold NEO as of Q1 2018.

Scholtz & Company reported no remaining NeoGenomics position as of Q1 2018 after selling out during the quarter.
Scholtz & Company sold 174,700 NeoGenomics shares in Q1 2018, an estimated $1.55M.
Scholtz & Company first reported a position in NeoGenomics in Q2 2016 and held it in 7 quarters.
Scholtz & Company's NeoGenomics position peaked at $2.43M in Q3 2017.
137 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2018.

Based on Scholtz & Company's 13F filing for Q1 2018, filed 11 May 2018.